Clinical Trial Update: Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating chidamide in combination with R-GDP for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• R-GDP

Snippet

Sponsor: Fudan University | Conditions: Chidamide, Lymphoma, B-Cell | Phase 2 | Status: UNKNOWN